REGENERON PHARMACEUT

REGN
Delayed Quote. Delayed  - 09/24 04:00:00 pm
638.9USD -1.18%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Number of employees : 9 123 people.
Sales per Business
20192020
Medicines7 863.40100%8 497.10100%
USD in Million
Sales per region
2020
United States5 567.6065.5%
Rest of World2 372.5027.9%
Other557.006.6%
USD in Million
Managers
Name Title
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Andrew J. Murphy Executive Vice President-Research
Bob McCowan Chief Information Officer & Senior VP-IT
Patrice Gilooly Senior VP-Quality Assurance & Operations
Beth F. Levine Chief Compliance Officer & Senior Vice President
Michael S. Brown Independent Director
Shareholders
Name Equities %
Fidelity Management & Research Co. LLC 10,160,966 9.67%
The Vanguard Group, Inc. 7,539,745 7.17%
Capital Research & Management Co. (World Investors) 5,307,957 5.05%
SSgA Funds Management, Inc. 4,516,716 4.30%
Wellington Management Co. LLP 4,057,382 3.86%
JPMorgan Investment Management, Inc. 2,818,824 2.68%
Loomis, Sayles & Co. LP 2,754,224 2.62%
Capital Research & Management Co. (Global Investors) 2,754,098 2.62%
Icahn Associates Holding LLC 2,444,081 2.33%
BlackRock Fund Advisors 2,424,737 2.31%
Company contact information
777 Road Old Saw Mill River
NY 10591 Tarrytown, New York


Phone : +1 (914) 847 7000
Fax :
web site : http://www.regeneron.com
Markets and indexes
- Nasdaq Global Select Market
- Nasdaq 100 / S&P 500, Stoxx Global 200
Stock Exchange Codes
- Reuters Code :  REGN.O
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS32.25%66 425
GILEAD SCIENCES, INC.22.19%89 259
BIONTECH SE309.08%80 542
WUXI APPTEC CO., LTD.34.39%68 685
VERTEX PHARMACEUTICALS-22.31%47 634
BEIGENE, LTD.46.88%35 310
GENMAB A/S12.87%28 627
ARGENX SE8.64%15 823
CUREVAC N.V.-28.41%10 301
ACCELERON PHARMA INC.31.04%10 210
ASCENDIS PHARMA A/S-1.67%9 322
NEUROCRINE BIOSCIENCES, INC.-0.90%8 990
MIRATI THERAPEUTICS, INC.-24.26%8 588
HUALAN BIOLOGICAL ENGINEERING INC.-33.31%7 948
SAREPTA THERAPEUTICS, INC.-46.88%7 232
GW PHARMACEUTICALS PLC89.72%6 907
ARROWHEAD PHARMACEUTICALS, INC.-14.81%6 815
MARAVAI LIFESCIENCES HOLDINGS, INC.75.94%6 486
ULTRAGENYX PHARMACEUTICAL INC.-31.29%6 452
EXELIXIS, INC.1.40%6 411
REMEGEN CO., LTD.7.16%6 405
Brand Portfolio
» More brands of Regeneron Pharmaceuticals